Definition of a Gene: Structure, Expression, Regulation and Clinical Relevance

A gene is a functional unit of heredity encoded in DNA. In modern genetics, a gene is not simply a short stretch that “makes one protein.” A gene includes a transcribed sequence and its regulatory context; it may produce a protein, a functional RNA or several products through alternative processing. Gene structure and regulation explain normal development, inherited disease, cancer, pharmacogenomics and many emergency presentations.

Learning outcomes

By the end of this page, the learner should be able to define a gene and related terms, describe DNA structure and gene organisation, explain transcription, RNA processing and translation, discuss regulation and epigenetics, classify common variants and inheritance patterns, and interpret basic genetic information in clinical practice.

1. What exactly is a gene?

Classical genetics described a gene as a unit that controls an inherited characteristic. Molecular genetics defines it more precisely as a genomic region whose sequence and regulation produce a functional product—usually a protein or a functional RNA—and whose variants can be transmitted through cell division or reproduction. The boundaries of a gene may include promoters, untranslated regions, exons, introns, enhancers and other regulatory elements that can lie some distance away.

Not every DNA segment is a gene, and one gene does not always equal one trait. Most clinically important traits result from interactions among multiple genes, regulatory networks and the environment. A single gene can also influence several organ systems (pleiotropy), and the same phenotype can arise from variants in different genes (genetic heterogeneity).

2. Key vocabulary

Term	Meaning	Clinical use
Genome	All genetic material in a cell or organism	Whole-genome testing surveys coding and non-coding regions
Chromosome	One organised DNA-protein molecule in the nucleus	Chromosome number or structure may be abnormal
Locus	Physical genomic location	Describes where a gene or variant lies
Allele	One sequence version at a locus	People usually carry two alleles of autosomal loci
Genotype	Individual’s genetic constitution at one or more loci	For example, two different alleles are heterozygous
Phenotype	Observable or measurable characteristics	Includes symptoms, laboratory values and response to treatment
Variant	A DNA sequence difference; significance must be interpreted	May be benign, pathogenic or of uncertain significance
Mutation	Older broad term for a sequence change; often replaced by “variant”	Use precise language and avoid assuming pathogenicity
Haplotype	Set of linked alleles inherited together	Useful in ancestry, linkage and some disease associations

3. DNA as the genetic material

3.1 Chemical structure

DNA is a double-stranded polymer of nucleotides. Each nucleotide contains a deoxyribose sugar, phosphate and one nitrogenous base: adenine (A), thymine (T), cytosine (C) or guanine (G). A pairs with T and C pairs with G through hydrogen bonds. The strands are complementary and antiparallel, allowing one strand to guide accurate copying of the other.

3.2 Packaging

DNA wraps around histone proteins to form nucleosomes. Nucleosomes fold into chromatin, which is organised into chromosomes during cell division. Open, relatively accessible euchromatin is generally more transcriptionally active; compact heterochromatin is less accessible, although the relationship is context-dependent.

3.3 Coding and non-coding DNA

• Protein-coding genes contain exons that contribute to the coding sequence, but exons can also include untranslated regions.
• Non-coding genes produce functional RNAs such as ribosomal RNA, transfer RNA, microRNA and long non-coding RNA.
• Regulatory DNA includes promoters, enhancers, silencers, insulators and boundary elements. A regulatory variant can alter expression without changing the protein sequence.

4. Gene organisation

Region	Function	Variant consequence
Promoter	Near the transcription start site; recruits transcription machinery	Reduced or abnormal transcription
Enhancer/silencer	Regulates expression, sometimes far from the gene	Cell-specific or developmental expression change
5′ untranslated region	Helps regulate RNA stability and translation	Altered translation or RNA processing
Exon	Retained in mature RNA; may encode protein or untranslated sequence	Missense, nonsense, synonymous or splice-related effect
Intron	Removed from pre-mRNA; contains regulatory information in some genes	Splice disruption or cryptic exon inclusion
3′ untranslated region	Controls stability, localisation and translation through regulatory elements	Abnormal mRNA half-life or protein amount
Polyadenylation signal	Directs cleavage and poly(A) tail addition	Unstable or incorrectly processed RNA

5. From gene to function: the flow of genetic information

5.1 Transcription

Transcription factors bind regulatory DNA and recruit RNA polymerase. The enzyme reads the template strand and synthesises a complementary RNA transcript. Transcription is cell-specific: a hepatocyte and a neuron contain essentially the same genome but express different sets of genes.

5.2 RNA processing

In eukaryotic cells, the primary transcript is capped at the 5′ end, introns are removed by splicing and a poly(A) tail is added. Alternative splicing allows one gene to produce different mRNA and protein isoforms. Splicing can be altered by variants at canonical splice sites, branch points, enhancers or silencers.

5.3 Translation

Ribosomes read mRNA codons and join amino acids into a polypeptide. Transfer RNAs match codons with amino acids; start and stop codons define the open reading frame. The protein then folds, may be cleaved or chemically modified, and is transported to its functional location.

5.4 RNA genes and non-coding function

Some genes do not produce proteins. Ribosomal and transfer RNAs are core components of translation; microRNAs can reduce translation or destabilise target mRNAs; long non-coding RNAs influence chromatin and transcription. A variant in a non-coding gene can therefore cause disease even when all protein-coding exons are normal.

6. Regulation of gene expression

• Transcription factors: proteins that activate or repress sets of genes in response to developmental, hormonal, metabolic or stress signals.
• Chromatin remodelling: nucleosome repositioning changes DNA accessibility.
• DNA methylation: often reduces transcription when promoter CpG regions are methylated, although context matters.
• Histone modification: acetylation, methylation and other marks alter chromatin interactions.
• RNA-level control: splicing, editing, microRNA binding, localisation and degradation control the amount and type of protein made.
• Feedback loops: products can inhibit or stimulate their own synthesis, maintaining homeostasis.

Environment and experience influence expression without changing the DNA sequence. Hypoxia, inflammation, hormones, nutrition, toxins and medicines can activate or repress gene networks. Epigenetic marks can persist through cell divisions, but they are not equivalent to a permanent DNA mutation.

7. Alleles, variants and their consequences

Variant type	Definition	Possible functional effect
Single-nucleotide variant	One base differs	Benign, missense, nonsense, splice or regulatory effect
Insertion/deletion	Bases added or removed	Frameshift if not in a multiple of three; altered protein if in-frame
Copy-number variant	Deletion or duplication of a larger segment	Changed gene dosage
Repeat expansion	Short sequence repeats beyond a pathogenic threshold	Anticipation or toxic RNA/protein effects
Structural variant	Inversion, translocation or complex rearrangement	Gene disruption, fusion or altered regulation
Regulatory variant	Change in promoter, enhancer or untranslated region	Abnormal amount, timing or tissue distribution

7.1 Protein-level categories

• Synonymous: codon changes but the same amino acid is encoded; can still affect splicing or RNA stability.
• Missense: one amino acid is replaced; effect depends on position, conservation and biochemical change.
• Nonsense: a premature stop codon may produce a truncated protein or trigger nonsense-mediated decay.
• Frameshift: insertion/deletion shifts the reading frame and often creates a premature stop.
• Loss-of-function: reduced or absent normal activity.
• Gain-of-function: increased, new or inappropriate activity.
• Dominant-negative: an abnormal product interferes with the normal allele’s product.

Clinical laboratories classify variants with evidence categories such as pathogenic, likely pathogenic, uncertain significance, likely benign and benign. A variant of uncertain significance should not be used alone to make irreversible clinical decisions.

8. Inheritance concepts

8.1 Autosomal dominant

One pathogenic allele can be sufficient for disease. Affected individuals often appear in successive generations, but reduced penetrance, new variants and variable expression can obscure the pattern. Each child of a heterozygous affected parent may have a 50% chance of inheriting the variant, but actual disease risk depends on penetrance.

8.2 Autosomal recessive

Disease usually requires pathogenic variants in both alleles. Parents may be unaffected carriers. Consanguinity increases the chance that both parents share a rare ancestral allele, but recessive disease occurs in every population.

8.3 X-linked and Y-linked

X-linked conditions show sex-dependent patterns because males have one X chromosome. Female expression may vary with X-inactivation. Y-linked traits pass from father to son. Do not infer inheritance from sex alone; confirm with the pedigree and molecular result.

8.4 Mitochondrial inheritance

Mitochondria have their own DNA, usually inherited maternally. Heteroplasmy—the mixture of normal and variant mitochondrial genomes—produces variable tissue involvement and severity.

8.5 Complex and multifactorial traits

Blood pressure, diabetes, asthma and many congenital conditions arise from many genes interacting with nutrition, infection, environment and behaviour. A family history can increase risk without following a simple Mendelian ratio.

9. Penetrance, expressivity, mosaicism and pleiotropy

• Penetrance: proportion of people with a genotype who show the phenotype. Reduced penetrance means a carrier may appear unaffected.
• Variable expressivity: affected people show different severity or organ involvement.
• Mosaicism: genetically distinct cell populations arise from a post-zygotic variant; distribution depends on timing and tissue lineage.
• Chimerism: one individual contains cell lines from different zygotic origins, for example after twin fusion or transplantation.
• Anticipation: some repeat-expansion disorders present earlier or more severely in successive generations.
• Pleiotropy: one gene influences multiple apparently unrelated traits.

10. Genes in clinical and emergency medicine

Clinical setting	Genetic contribution	Emergency relevance
Sudden arrhythmia or syncope	Channelopathies and cardiomyopathies	Family history and ECG may trigger specialist evaluation and family screening
Severe drug reaction	Pharmacogenetic susceptibility plus exposure	Stop the suspected drug, treat the emergency and record the reaction clearly
Unexplained neonatal illness	Metabolic or structural genetic disorder	Consider hypoglycaemia, acidosis, hyperammonaemia or seizures; involve metabolic specialists
Recurrent thrombosis or bleeding	Inherited coagulation or platelet disorder	Interpret history and tests before transfusion or anticoagulation decisions
Family clustering of cancer	Inherited predisposition or shared environment	Urgent presentation may reveal a syndrome; refer for counselling rather than ad hoc testing

Genetics does not replace immediate clinical care. Stabilise airway, breathing, circulation, glucose, seizures, shock or sepsis first, then arrange appropriate testing and counselling.

11. Genetic testing: what a result can and cannot say

• Diagnostic testing: evaluates a symptomatic patient for a suspected condition.
• Carrier testing: identifies a person who may transmit a recessive or X-linked condition.
• Predictive testing: estimates future risk in an asymptomatic person with a familial variant; requires consent and counselling.
• Prenatal and newborn screening: identify selected conditions for early treatment, not every possible disease.
• Somatic testing: examines tumour or acquired tissue variants and may guide targeted therapy; it does not automatically describe inherited risk.

Interpret results in the patient’s phenotype and family context. A negative test may mean the tested gene or method did not detect a cause, not that genetic disease is impossible. A positive result may indicate predisposition rather than certainty of disease.

12. Ethical and communication principles

• Obtain informed consent and explain possible results, uncertainty and implications for relatives.
• Protect confidentiality; genetic information may affect family members, insurance or employment depending on local law.
• Use non-directive counselling and respect reproductive choices.
• Avoid deterministic language such as “the gene caused everything.” Genes influence risk through biology and context.
• Use a trained genetic counsellor or specialist when testing may change major medical or reproductive decisions.

13. A practical pedigree and history approach

1. Ask about the presenting phenotype, age at onset, severity, triggers and organ systems.
2. Record a three-generation family history, including miscarriages, stillbirths, sudden unexplained death, developmental delay, recurrent thrombosis, unusual cancers and consanguinity.
3. Document ancestry respectfully without assuming a disease is limited to one group.
4. Identify medications, environmental exposures and non-genetic mimics.
5. Refer for targeted testing when the phenotype and family pattern justify it; do not order broad tests without a plan for interpretation.

References and further reading

• NCBI Bookshelf: Genes and Chromosomes.
• MedlinePlus Genetics: What is a gene?.
• National Human Genome Research Institute genetics glossary.
• Use local genetics, newborn-screening, consent and data-protection policies when applying genetic information.